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The  production  of  recombinant  human  granulocyte-colony  stimulating  factor  (hG-CSF)  for
therapeutic  purposes  relies  on its expression  in  selected  clones  of  transfected  mammalian
cells.  Alternatively,  this  protein  can  be produced  by  targeted  secretion  in  the  milk  of trans-
genic goats.  Thus,  the  aim  of  this  study  was  to  produce  founder  transgenic  goats  expressing
hG-CSF and  to propagate  a transgenic  production  herd.  After  DNA microinjection  of in vivo-
produced  pronuclear  embryos  was performed,  two  founders  were  obtained  (one  male  and
one  female,  named  10  M and  12  F,  respectively).  The mean  level  of hG-CSF  secreted  in  the
milk from  the  12 F  goat,  which  was  measured  during  a period  of induced  lactation,  was
620.92  ±  179.93  g/ml.  In addition,  the  recombinant  protein  presented  in  vitro  biological
activity  on  differentiation  of human  umbilical  stem  cells  to neutrophil  granulocyte  series.
A total  of  nine  kids  (six from  10  M  and  three  from  12  F) that  carried  the  hG-CSF  transgene
were  generated  by outbreeding  of the  founders.  In  summary,  we produced  two transgenic
goats  with  a  stably  integrated  hG-CSF  gene  that  were  capable  of secreting  recombinant  hG-
CSF  from  the  lactating  mammary  gland  without  causing  any  harm  to the  animals’  health.
Additionally,  the founders  proved  to  be fertile  and  capable  of  transmitting  the hG-CSF  gene
to  ﬁrst  generation  progeny  of each  line.  Additional  investigations  of  the  phenotypic  and
ristics  
 genotypic  characte
. IntroductionThe production of recombinant human proteins with
harmaceutical uses in the milk of transgenic animals is
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sometimes referred to as “gene pharming”. This technology
can overcome the limitations facing traditional recom-
binant pharmaceutical protein production systems. The
mammary gland is the preferred protein production site,
due to the quantities of protein that can be produced and
the ease of protein production (Niemann and Kues, 2007).
Open access under the Elsevier OA license.The generation of transgenic cattle is prohibitively
expensive, due to the long gestation period, small litter
size and high maintenance costs associated with cattle. For
these reasons, the use of dairy goats as bioreactors provides
inant R
3  min  at 95 ◦C, (b) 35 cycles of 30 s at 95 ◦C, 30 s at 55 ◦C and 30 s at 72 ◦C,
and (c) 5 min  at 72 ◦C. The amplicons were analyzed by electrophore-106 V.J.F. Freitas et al. / Small Rum
signiﬁcant advantages. Several studies have demonstrated
the production of transgenic goats for the secretion of valu-
able proteins in their milk (Ebert et al., 1991; Ko et al.,
2000; Maga et al., 2006). In addition, the Food and Drug
Administration’s market authorization of ATryn®, GTC Bio-
therapeutic’s recombinant human antithrombin, validated
goat transgenic technology as a viable alternative method
for the production of recombinant pharmaceutical proteins
(Lavine, 2009).
Once a founder goat that has a stably integrated trans-
gene and is correctly expressing the gene in the mammary
glands has been produced, propagation of a transgenic
herd may  be initiated. The necessary size of the transgenic
herd depends on the demand for that speciﬁc recombinant
protein. When the demand only requires a few animals,
the production of founder animals using a proven cell
line could generate the needed supply. However, when
large herds are needed to meet market demands, more
traditional breeding or assisted reproductive technologies
may  be used. Embryos can be obtained from a transgenic
female founder using either standard multiple ovulation
and embryo recovery techniques or by in vitro embryo
production. Moreover, male founders can be readily propa-
gated using standard artiﬁcial insemination (AI) techniques
(Keefer, 2004).
Our group initiated studies with the goal of producing
the human granulocyte-colony stimulating factor (hG-CSF)
in the milk of transgenic goats (Freitas et al., 2007). The
hG-CSF protein is central to neutrophil-based immune
defenses, due to its regulatory roles in the growth, differ-
entiation, survival and activation of neutrophils and their
precursors (Barreda et al., 2004). Following its molecu-
lar cloning and subsequent production as a recombinant
human protein (Nagata et al., 1986; Souza et al., 1986), hG-
CSF has been the most widely used hematopoietic growth
factor due to its proven efﬁcacy against different forms
of neutropenia and chemotherapy-induced leukopenia, as
well as for mobilization of progenitor cells for autologous
or allogeneic transplantation (Welte et al., 1996).
In this study, we describe the production of transgenic
founder goats for hG-CSF secretion, a partial description of
the phenotypic characteristics of the founders, including
milk hG-CSF production, and the propagation of a trans-
genic herd using AI and embryo transfer techniques.
2. Materials and methods
2.1. Animal ethics and biosafety
All animal protocols used in this work were approved by the Animal
Ethics Committee of the State University of Ceará (CEUA/UECE 12/05) and
Brazil’s Biosafety Technical National Committee (CTNBio 228/06). Addi-
tionally, all studies were conducted according to the guidelines for the
ethical use of animals in research (ASAB, 2006).
2.2. Animals
To obtain the hG-CSF transgenic founders, Canindé goats were used
for  in vivo pronuclear embryo production. Eleven females were selected
as  embryo donors, which were fertilized by two males. Twenty goats of
an undeﬁned breed were used as the recipients for the microinjected
embryos. To maintain the transgenic lines and generate progeny, the
transgenic founders were bred to non-transgenic Canindé goats. For this
step, seven non-transgenic females and two  non-transgenic males wereesearch 105 (2012) 105– 113
used to obtain the progeny of the male and female transgenic lines, respec-
tively. Additionally, ﬁve females of an undeﬁned breed were used as
embryo recipients. All animals were housed indoors in groups of ﬁve
animals per pen with controlled nutrition. To maintain animal welfare
standards, goats also had access to Tifton (Cynodon dactylon) pasture for
four hours a day. Goats were maintained with a high-quality concentrate
(20% crude protein), water and mineral blocks.
2.3. Pronuclear embryo production
The embryo donors were subjected to a hormonal treatment for estrus
synchronization and superovulation, as described by Moura et al. (2010).
The recipient females received the same estrus synchronization treatment
with an additional intramuscular injection of 300 IU eCG (Novormon, Syn-
tex, Buenos Aires, Argentina) 48 h prior to the end of the treatment. Within
36 h after the hormonal treatment, bucks with proven fertility were mated
to  the donors. The donors were fasted 24 h prior to surgery, and the
embryos were recovered 72 h after the hormonal treatment. To harvest
the  embryos, a medial ventral incision was made, and the oviduct was
ﬂushed with sterile phosphate-buffered saline (Freitas et al., 2007). The
recovered medium was examined under a stereomicroscope (SMZ-800,
Nikon, Kawasaki, Japan) for the identiﬁcation of the ova/embryos.
2.4. DNA microinjection and embryo transfer
The pGoatcasGCSF expression vector with a long 5′ ﬂanking sequence
of  goat s1-casein gene (CSN1S1) was  previously designed and used to
produce mice transgenic lines (Serova et al., in press). The pGoatcasGCSF
construct was  digested with the restriction enzymes SalI and XhoI and the
DNA fragments were separated by electrophoresis in a 0.7% agarose gel
using a Tris–acetate-EDTA (TAE) buffer. A 6391 bp DNA fragment (Fig. 1A)
was  isolated from the gel using Qiagen columns (QIAGEN Ltd., West Sus-
sex, UK) according to the manufacturer’s recommendations. Puriﬁed DNA
was  dissolved in 0.01 M Tris–HCl 0.25 mM EDTA, pH 7.4 and injected in
pronuclear goat embryos, as described earlier (Freitas et al., 2007). Thus,
the harvested embryos were pooled together and placed in 100 l droplets
of  M16  medium (Sigma–Aldrich, St. Louis, MO,  USA) supplemented with
10% fetal bovine serum (Nutricell, Campinas, Brazil). After centrifugation
(12,100 × g for 4–6 min), the zygotes with visible pronuclei were microin-
jected under an inverted microscope with DIC optics (Nikon TE2000,
Kawasaki, Japan) using a pair of micromanipulators (Narishige, Tokyo,
Japan). The embryos were cultured for 1–2 h at 37 ◦C with 5% CO2 to eval-
uate the post-injection survival. The surviving zygotes were maintained
in culture media until they were transferred to recipients with at least one
recent ovulation. Three to six embryos were transferred per recipient.
2.5. Transgene detection
The hG-CSF transgene was detected in skin biopsies from the ears of
two-week-old founders using PCR ampliﬁcation according to the method
reported by Freitas et al. (2007). The identiﬁcation of transgenic animals
carrying the DNA construct was conducted by polymerase chain reaction
(PCR) with two pairs of primers: PrA (forward): 5′-AAA GGA TAA GGC
TAA  TGA GG-3′ , PrB (reverse): 5′-CGT TGT ACT TTT GTA CTG AGC-3′; PrC
(forward): 5′-TCT GCA AAA GCA GGC TAA AGG-3′ , PrD (reverse): 5′-GCC
AAG ACA CTC ACC CAT CAG-3′ . Primers PrA and PrD are complementary
to the hG-CSF gene and to the 3′-polyA region of the bovine CSN1S1 gene,
respectively, whereas PrB and PrC are complementary to the 5′-ﬂanking
sequence of the goat CSN1S1 gene and to the hG-CSF gene, respectively
(Fig. 1A). Sizes of PCR products were 704 bp for PrA–PrB and 530 bp for
PrC–PrD primer pairs. DNA samples were obtained by phenol–chloroform
extraction according to the protocol described by Sambrook et al. (1989).
The PCR ampliﬁcations were performed using 50 ng of genomic DNA, 2 M
of  each primer and 0.25 U of GoTaq DNA polymerase (Promega, Madison,
WI,  USA). The thermal cycling was performed with the following steps: (a)sis on a 1.5% agarose gel and visualized by ethidium bromide staining.
Ampliﬁcation of the -actin gene was  performed as the reaction control.
Additionally, genomic DNA samples from a non-transgenic goat and an
hG-CSF transgenic goat (previously obtained by Freitas et al., 2007) were
used as the negative and positive controls, respectively.
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Fig. 1. (A) The 6391 bp DNA fragment digested from pGoatcasGCSF expression vector used for the generation of transgenic goat. From left to right: goat
CSN1S1 gene 50 – regulatory region; exon 1 (E1), intron 1, and a part of exon 2 (E2) of the goat CSN1S1 gene; a full-sized genomic human GCSF gene;
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.6.  Hematological analysis, serum biochemistry, hG-CSF
uantiﬁcation and clinic evaluations
Transgenic founders (one male and one female) and non-transgenic
oats (one male and one female) were subjected to hematological and
erum biochemistry examinations of samples taken at regular intervals
rom 45 to 280 days of age. Blood samples were collected for both white
lood cell (WBC) counts (total and differential) and serum biochem-
stry (urea, creatinine, glucose, aspartate transaminase-AST and alanine
minotransferase-ALT), which were performed using a Cell-Dyn 3700
ematology analyzer (Abbott Laboratories Diagnostic Division, IL, USA)
nd BT 3000 plus (Winer Lab, Rosário, Argentina), respectively. The data
ere presented as the mean ± SD and qualitatively compared with the
ormal reference values for goats (Pugh, 2002). Additionally, six serum
amples were used to determine the concentration of serum hG-CSF by
LISA assay (Human G-CSF ELISA kit, RayBiotech, Norcross, GA, USA)
fter a 1:10 (v:v) dilution in the standard diluent buffer provided by
he manufacturer. Immediately before the blood collection, the follow-
ng  parameters were checked in the animals: rectal temperature, heart
ate, respiratory rate, inspection of ocular mucosa and palpation of lymph
odes..7. Induced lactation and quantiﬁcation of hG-CSF in the milk
Lactation was  hormonally induced in ten-month-old female goats
one transgenic and one non-transgenic) according to the protocol
escribed by Cammuso et al. (2000).  Brieﬂy, estrogen (0.25 mg/kg, ECP,1S1 gene. Additional notations: PrA, PrB, PrC, PrD—positions for primers
d for obtaining progeny from the founder transgenic goats for hG-CSF
Pﬁzer, São Paulo, Brazil) and progesterone (0.75 mg/kg, Aﬁsterone, Osasco,
São Paulo, Brazil) were given on alternate days for a total of seven adminis-
trations. On day 13, prednisolone (0.40 mg/kg, Corti-dural 20, Avellaneda,
Argentina) was injected daily for three days. Milk samples were collected
for  approximately 100 days. Six samples (selected at the beginning, mid-
dle  and end of lactation) of whey fraction were obtained by centrifugation
(17,900 × g for 15 min), and the concentration of hG-CSF was determined
by  ELISA assay (Hu G-CSF ELISA kit, Invitrogen, Camarillo, CA, USA) on a
1:100,000 (v:v) dilution of the whey fraction in the standard diluent buffer
provided by the manufacturer.
2.8. Western blotting analysis
The whey proteins from milk samples that had been diluted 1:5 (v:v)
in  water were separated on a 12.5% polyacrylamide gel using sodium
dodecyl sulfate (SDS-PAGE) electrophoresis according to the method
described by Laemmli (1970). Next, the proteins were electrophoretically
transferred onto a Hybond P PVDF membrane (GE Healthcare Bio-Sciences
Corp., Piscataway, NJ, USA) using the protocol described by Sambrook et al.
(1989).  The membrane was  blocked with a solution of 5% nonfat dried
milk in PBS (w/v) with 0.1% (v/v) Tween 20 and incubated in 2 g/ml anti-
human G-CSF monoclonal antibody (Sigma–Aldrich, Saint Louis, MO,  USA)
at  25 ◦C for 2.5 h. After incubation with the primary antibody, the mem-
brane was  then incubated in a 1:10,000 dilution of anti-mouse IgG alkaline
phosphatase conjugate (Sigma Chemical Co., Saint Louis, MO,  USA) at 25 ◦C
for  1 h. The membrane was  developed using a BCIP/NBT substrate solution
(SigmaFast, Sigma Chemical Co., Saint Louis, MO,  USA).
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Fig. 2. The identiﬁcation of hG-CSF transgenic goats using PCR analysis.
The amplicons produced by PCR from genomic DNA with the PrA/PrB (AB),
PrC/PrD (CD) or -actin (Act) primers were run on an agarose gel and visu-
alized by ethidium bromide staining. The lanes contain PCR products from
the 10 M founder (lane 2), a non-transgenic goat (lane 3), the 12 F founder
(lane 4) and hG-CSF transgenic goat (lane 6) previously obtained by Freitas
et  al. (2007). Ampliﬁcation of the -actin gene served as the positive con-
trol, and omission of the template served as the negative control (lane 5).
The molecular weight marker is a 100 bp ladder (lanes 1 and 7).
Fig. 3. The detection of the hG-CSF gene in the spermatozoa of the 10 M
transgenic founder using PCR analysis. The amplicons produced by PCR
from genomic DNA with the PrA/PrB (AB), PrC/PrD (CD), or -actin (Act)
primers were run on an agarose gel and visualized by ethidium bromide
staining. The lanes contain PCR products from semen DNA (lanes 2 and108 V.J.F. Freitas et al. / Small Rum
2.9. Estimation of hG-CSF biological activity in the milk
Samples of umbilical human cord blood were diluted 1:2 in TCM199
(Sigma, USA) for hematocrit reduction. Total nucleated cells were obtained
after sedimentation of erythrocytes with Hespan (Hydroxyethyl starch,
McGaw Inc., Irvine, CA, USA) added at a ratio of 1:6; they were then
homogenized and kept at room temperature for 30 min. The top layer,
rich  in nucleated cells, was transferred to another tube and mixed. Plates
were previously prepared with 1 ml  of “Iscove’s” medium containing 3%
agar (Sigma, USA) and 20% calf fetal serum (Sigma, USA), creating a semi-
solid layer to prevent cell adhesion. The prepared plates were seeded
with 5 × 105 total nucleated cells in 1 ml  of Iscove’s medium contain-
ing 2% agar at 38 ◦C, 20% calf fetal serum and milk. Either recombinant
hG-CSF (Filgrastim, Blaüsiegel, Brazil) at a ﬁnal concentration of 50 ng/ml
(positive control) or aliquots of milk whey fraction of the transgenic and
non-transgenic (negative control) goat were added to the gel or the cell
suspension. The transgenic goat milk was added to a ﬁnal hG-CSF concen-
tration of 50; 100; 200 ng/ml, established previously by ELISA. Cultures
were maintained for 12 days in an incubator at 37 ◦C with 5% CO2. The
plates were ﬁxed with formalin gas for at least 12 h. The colonies (groups
of  cells with more than 20 cells) were quantiﬁed using the inverted micro-
scope (Nikon TE2000, Kawasaki, Japan). For morphological identiﬁcation
of  cells, the layers of agar were transferred to slides, dehydrated, and
stained by May-Grünwald–Giemsa. The G-CSF activity was expressed in
colony-forming units (CFU). The signiﬁcance of the differences between
groups was assessed by ANOVA followed by Tukey test (P < 0.01).
2.10. Transgene transmission to progeny
Before F1 offspring from the founder had been obtained, the trans-
gene was  detected in the spermatozoa of the 10-month-old transgenic
male founder by PCR using the method previously described for skin biop-
sies. The strategy used to obtain the founder offspring is demonstrated in
Fig. 1B. Non-transgenic Canindé female goats were estrus-synchronized
and made pregnant using AI or natural breeding with the founder male.
After estrus synchronization and superovulation (as described in Section
2.3),  the founder female was fertilized by a non-transgenic Canindé buck,
and the embryos were recovered and evaluated under a stereomicroscope
according to established guidelines (Stringfellow and Givens, 2009). After
evaluation, the embryos were transferred to non-transgenic goats of an
undeﬁned breed. After the birth of the founders’ progeny, both the sexual
proportion and the transgene transmission efﬁciency were analyzed by
Pearson’s chi-squared test.
3. Results
All of the goats that were used as embryo donors
responded to the hormone treatment and produced 109
total embryos or ova, including 79 (72.5%) embryos in the
pronuclear stage. After microinjection and embryo trans-
fer, 12 recipients became pregnant and produced 18 kids,
including one male (10 M)  and one female (12 F) that car-
ried the hG-CSF transgene (Fig. 2). Thus, the transgenic rate
was 11.1% (2/18) based on offspring produced and 3.3%
(2/61) based on the number of microinjected/transferred
embryos. The two transgenic founders remained healthy
throughout the experimental period and thereafter. At
280 days of age, both the male and female were sexually
active. The male demonstrated a normal libido and his
semen contained normal sperm cells that carried the hG-
CSF transgene (Fig. 3).
The hematological analyses of WBCs in the peripheral
blood of transgenic founders and non-transgenic controls
from 45 to 280 days are shown in Table 1. Regardless of
the relatively high average values for transgenic goats, neu-
trophil counts were not stable over time, decreasing from
45 to 160 day-of-old. Subsequent counts have reached val-
ues near the upper limit of the normal range for goats.
3)  or skin DNA (lanes 4 and 5) from the founder (lanes 2 and 4) or a non-
transgenic goat (lanes 3 and 5). Ampliﬁcation of the -actin gene served as
the positive control, and omission of the template served as the negative
control (lane 6). The molecular weight marker is a 100 bp ladder (lanes 1
and 7).
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Table  1
Analysis of white blood cells (WBC) in hG-CSF transgenic and non-transgenic goats.
Group Sex
Number of cells × 103/l (mean ± SD)a
WBC
Granulocytes
Lymphocytes Monocytes
Neutrophils Basophils Eosinophils
Transgenic
Male 27.29 ± 12.39 21.86 ± 12.07 0.02 ± 0.06 0.61 ± 1.11 4.47 ± 1.86 0.32 ± 0.30
Female 21.84 ± 9.58 14.83 ± 9.06 0.06 ± 0.12 0.54 ± 0.48 5.93 ± 1.72 0.47 ± 0.28
Non-transgenic
Male 10.99 ± 2.27 4.79 ± 0.85 0.07 ± 0.06 0.52 ± 0.76 5.32 ± 2.11 0.29 ± 0.18
Female 5.91 ± 2.01 2.49 ± 1.28 0.06 ± 0.06 0.09 ± 0.08 3.02 ± 1.42 0.24 ± 0.19
Normal rangeb 4.0–13.0 1.2–7.2 0–0.12 0.05–0.65 2.0–9.0 0–0.55
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ba The mean (±SD) of 18 observations per animal are presented for bot
emale) goats.
b Pugh (2002).
espite of the neutrophil oscillations, hG-CSF was  not
etected in serum samples using high sensitivity ELISA
ssay (from 1 pg/ml). Additionally, the hematological ﬁnd-
ngs were not accompanied by changes in other cell counts,
iochemistry serum measurements (Table 2) or clini-
al parameters. Thus, lymphocyte, monocyte, eosinophil
nd basophil counts, as well as serum glucose, urea,
reatinine, AST and ALT, rectal temperature, heart and
espiratory rates for transgenic and non-transgenic were
ithin the normal ranges of values for goats (Pugh, 2002).
ll animals had palpable lymph nodes of normal size and
exture.
able 2
arameters of serum biochemistry in hG-CSF transgenic and non-transgenic goat
Group Sex Urea (mg/dl)a Creatinine (mg/
Transgenic Male 37.00 ± 9.44 0.85 ± 0.21 
Female 42.89 ± 12.27 0.74 ± 0.16 
Non-transgenic Male  40.89 ± 17.32 0.82 ± 0.16 
Female 34.44 ± 5.80 0.76 ± 0.12 
Normal  rangeb 21.4–42.8 0.7–1.8 
a The mean (± SD) of 18 observations per animal are presented for both trans
emale) goats.
b Boyd (1984), Kaneko et al. (1997).
ig. 4. The expression of hG-CSF in the milk of the 12 F female transgenic goat. 
lanes  4 and 7), as well as an E. coli-derived, non-glycosylated hG-CSF (lanes 3 and
olecular weight standards are shown in lane 1. The arrows in panel (B) show the
and)  forms of hG-CSF in the milk of the transgenic goat. The E. coli-derived hG-Cenic (one male and one female) and non-transgenic (one male and one
Both the transgenic and the non-transgenic females
produced milk after the hormonal induction of lacta-
tion. The average concentration of hG-CSF produced by
the transgenic female was 620.92 ± 179.93 g/ml of milk.
According to western blot analysis, two  different forms of
hG-CSF were detected in the milk of the transgenic goat,
as shown in Fig. 4. After an image analysis using a protein
ladder as a reference, the upper and lower bands of hG-CSF
had apparent molecular weights of 19 and 16.5 kDa, respec-
tively. The hG-CSF produced in bacteria was detected as a
single band of 17 kDa. Additionally, the milk collected from
a non-transgenic female did not exhibit any hG-CSF bands.
s.
dl)a Glucose (mg/dl)a AST (U/l)a ALT (U/l)a
53.50 ± 15.36 89.17 ± 61.25 18.67 ± 22.29
59.57 ± 10.23 46.00 ± 13.56 16.28 ± 3.89
55.11 ± 16.82 97.00 ± 28.03 28.72 ± 18.34
56.28 ± 11.41 99.78 ± 36.17 18.17 ± 8.31
50–75 43–132 15–52
genic (one male and one female) and non-transgenic (one male and one
Milk from the transgenic goat (lanes 2 and 5) and a non-transgenic goat
 6) was subjected to SDS-PAGE (A) and western blotting (B) analyses. The
 positions of the non-glycosylated (lower band) and glycosylated (upper
SF contained only the non-glycosylated band.
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Fig. 5. The colony-forming assay performed on human umbilical cord
blood. Negative control (milk of non-transgenic goat); milk of transgenic
goat (containing 50, 100 and 200 ng/ml of hG-CSF) and positive control
(recombinant hG-CSF; Filgrastim, 50 ng/ml).
To determine the biological activity of hG-CSF in milk,
we examined its effect on precursor cells of human umbil-
ical cord blood in the colony-generating test (Fig. 5).
Addition of the milk of the transgenic goat containing
50 ng/ml of hG-CSF produced a signiﬁcant increase of the
number of the colonies when compared to negative control
with milk of non-transgenic goat (12.2 ± 4.2 versus 1.2 ± 0.9
CFU, P < 0.01). The same effect was produced by recom-
binant bacterial G-CSF given in the same concentration
(14.3 ± 2.9 versus 1.2 ± 0.9 CFU, P < 0.01). Morphological
examination of the colonies showed that they were com-
posed of characteristic granulocyte cells at different stages
of differentiation (Fig. 6).
The efﬁciency of transgene transmission from the
founding goats (10 M and 12 F) to their progeny is
Fig. 6. Analysis in light microscopy of the colonies formed after addition of trans
belong to the neutrophil granulocyte series. (A) 50 ng/ml; (B) 100 ng/ml; and (C) 
Table 3
Transgene transmission to the offspring from two hG-CSF transgenic goat lines.
Line
No. of
pregnancies
No. of
offspring
Offs
M 
10 M 7 11 6 (54
12  F 5 8 4 (50
Total 12  19 10 (5
The transgenic ratios for each line were compared with the expected value of 50%
a Percentage of the total offspring.
b Percentage of the transgenic animals.esearch 105 (2012) 105– 113
presented in Table 3. To date, a total of nine transgenic
(four females and ﬁve males) and ten non-transgenic (ﬁve
females and ﬁve males) kids have been produced by the
founders. In both 10 M and 12 F lines, the transgene segre-
gated equally among the male and female offspring and no
signiﬁcant differences (P > 0.05) were found between the
observed values and the expected 1:1 ratio.
4. Discussion
In this study, we report the generation and partial
characterization of two  transgenic goat lines for hG-CSF
expression in milk. Two transgenic founders were gener-
ated by pronuclear microinjection with a DNA construct
that contained the hG-CSF gene fused to goat s1-casein
promoter. The founders were healthy, fertile and able to
transmit their transgenes to the F1 progeny. Additionally,
the female founder was  able to express the recombinant
hG-CSF protein in her milk.
The transgenic rate after pronuclear microinjection,
obtained in this study, was  higher than the previously
reported range of 7–10% described for goats (Baldassarre
et al., 2004; Lee et al., 2000). The transgenic rate observed
in this study was also higher than that in our previous
reports, in which one transgenic Saanen goat represented
8.3% of the kids born and 0.7% of the transferred embryos
(Freitas et al., 2007). Formerly, we  reported that Canindé
goats had a more efﬁcient pronuclear embryo yield and a
higher rate of successful microinjection than did the Saanen
breed (Moura et al., 2010). Thus, in the present work, the
Canindé goats may  have produced higher-quality pronu-
clear embryos. This approach could explain the improved
transgenic rate, but other factors, such as the DNA construct
used, cannot be ruled out.
genic goat milk. The morphology of the colonies indicates that their cells
200 ng/ml of hG-CSF.
pring by sex (%)a Transgenic ratio (%)b
F M F Total
.5) 5 (45.5) 3 (50.0) 3 (50.0) 6 (54.4)
.0) 4 (50.0) 2 (66.7) 1 (33.3) 3 (37.5)
2.6) 9 (47.4) 5 (55.6) 4 (44.4) 9 (47.4)
 at a signiﬁcance level of 5%.
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The capability to hormonally induce the mammary
land to produce milk prior to the onset of natural lactation
an provide early milk for the detection of the prelim-
nary expression levels of recombinant proteins from a
ransgenic line (Maga and Murray, 1995). The ability to
ecrease the length of time to milk production could sig-
iﬁcantly impact the decision-making process regarding an
nimal’s genetic value within a transgenic founder devel-
pment program. In our study, the 12 F founder produced
ore than 600 g/ml of hG-CSF in its milk during an
nduced lactation. The actual quantity of hG-CSF in the
ilk was approximately 12 times greater than the yields
btained with the transgenic goat produced by Ko et al.
2000). Moreover, although we did not induced lactation
n the F1 females, these animals may  also express hG-CSF
n their milk similar to the female founder, since the expres-
ion of a transgene is essentially at a constant level in the
ifferent individuals of a line over number of generations
Colman, 1996).
Before the expression cassette was introduced into goat
mbryos, the expression of hG-CSF directed by goat s1-
asein was investigated in mice (Serova et al., in press).
hus, the pGoatcasGCSF expression vector was able to
irect tissue-speciﬁc secretion of hG-CSF into the milk of
ransgenic mice in the range of 19–40 g/ml. The variabil-
ty in milk hG-CSF concentration between murine lines
as low, in spite of the different integration sites of the
ransgene in the founders, and was signiﬁcantly lower than
evels in the previously generated transgenic mice with
he pGCm1 and pGCm2 expression vectors, in which hG-
SF concentration levels varied from 0.008 to 1000 g/ml
Dvorianchikov et al., 2005).
Lee et al. (2000) also generated transgenic goats (one
ale and one female) for the production of hG-CSF. The
uthors used the goat -casein promoter to regulate the
xpression of the cassette injected into the embryos. The
ransgenic female was able to produce hG-CSF in milk
t levels of up to 50 g/ml during natural lactation (Ko
t al., 2000). The authors reported that the transgene was
ot detected in the sperm DNA of the male transgenic
oat.
In the present work, we conﬁrmed that transgenic goats
ere true founders, as they were able to produce transgenic
escendants. To predict the birth of transgenic offspring
rom the 10 M line, we  tested the presence of the for-
ign gene in the spermatozoa before mating 10 M with
on-transgenic females. Thus, as expected, transgenic kids
ere obtained at a rate of 54.4% (6/11). Because most
ounding animals obtained by pronuclear microinjection
re hemizygous for the transgene, we would expect the
ransgene to be inherited by 50% of the offspring. Our
esults were not signiﬁcantly different from the expected
ransgenic ratio for the ﬁrst generation. Therefore, this line
pparently transmits the hG-CSF transgene in a Mendelian
ashion. Despite the apparent lower transgenic ratio in
he 12 F ﬁrst generation (37.5%), this ratio also did not
iffer signiﬁcantly from the expected 1:1 ratio. Addition-
lly, although the sex ratio in transgenic offspring did
ot differ signiﬁcantly from the expected value, the num-
er of observations remained low and will require further
onitoring.esearch 105 (2012) 105– 113 111
Glycosylation is undoubtedly one of the most important
post-translational modiﬁcations for therapeutic proteins
(Fussenegger et al., 1999) and plays an important role
in many biological processes including protein stability,
serum half-life, immune response, intracellular signaling
and cell–cell/cell–extracellular matrix interaction (Varki
et al., 1999). In the present study, the milk of the trans-
genic founder contained two  bands that corresponded
to recombinant hG-CSF by western blotting analysis.
Although speciﬁc biochemical analysis was  not performed,
we assumed the upper band to be a glycosylated (or more
glycosylated) form of hG-CSF and the lower band to be a
non-glycosylated (or less glycosylated) form of the protein,
when compared with the pattern of E. coli-derived (non-
glycosylated) hG-CSF band. The presence of both hG-CSF
forms in the milk of transgenic animals has already been
described in mice (Dvorianchikov et al., 2005) and goats
(Ko et al., 2000). Ko et al. (2000) reported that the inten-
sity of the non-glycosylated hG-CSF band was stronger than
that of the glycosylated band, as evaluated by densitom-
etry. However, the glycosylation of recombinant proteins
in the mammary gland is a particularly complex issue
(Houdebine, 2000, 2009), and the mechanism responsible
for the presence of two bands with different intensities
in the milk of our transgenic goat remains to be investi-
gated.
The human G-CSF protein speciﬁcally regulates the
in vivo proliferation and differentiation of neutrophilic
granulocyte precursor cells from the bone marrow (Nagata
and Fukunaga, 1991). In the present work, the two forms
of hG-CSF mixed in the milk of our transgenic founder
(12 F) presented an in vitro biological activity compara-
ble to E. coli-derived recombinant hG-CSF and statistically
greater than negative control (non-transgenic milk). The
morphological examination of colonies showed character-
istic granulocyte cells at different stages of differentiation.
These results indicate the functional validity of hG-CSF in
the transgenic goat milk as was observed by Serova et al.
(in press) using the same expression vector in mice.
In light of this recombinant protein being produced in
the mammary gland, the potential for systemic in vivo bio-
logical activity in the transgenic animal is a possibility
and has previously been reported (Massoud et al., 1996;
Ko et al., 2000; Kim et al., 2006). Therefore, the serum
levels of hG-CSF were evaluated in the transgenic goats
to investigate the possibility of ectopic hG-CSF expres-
sion. Leukocyte parameters were evaluated because this
cytokine can act on blood cells in the granulocytic lineage.
Interestingly, despite the measured dynamic changes in
WBC  and neutrophil counts prior to 280 days of life, the
transgenic goats in the present study had no detectable
of serum hG-CSF. Despite the use of a highly sensitive
ELISA assay, ectopic expression of serum hG-CSF below
1 pg/ml cannot be ruled out. However, this level proba-
bly would not explain the blood cell changes observed in
transgenic goats because only hG-CSF serum levels higher
than 1 ng/ml have been reported to produce granulocyto-
sis and lymphocytosis in transgenic mice (Yamada et al.,
1996). Moreover, our transgenic founders have no changes
in other granulocytic and non-granulocytic cell counts,
which, together with the non-transgenic animals, were
inant R112 V.J.F. Freitas et al. / Small Rum
within the normal ranges for goats (Pugh, 2002). Another
possibility is that transgene expression in tissues other
than the mammary gland occurs and is able to alter the
blood cellularity through a non-endocrine action. However,
Serova et al. (in press) used RT-PCR and immunoﬂuorescent
analysis to conﬁrm the precise tissue-speciﬁc expression
of hG-CSF in the mammary glands of four mice lines pro-
duced with the same DNA construct used in the present
work.
For the 10 M line, we do not have any information
regarding hG-CSF expression in the milk, as induced lac-
tation was not performed in the male founder to avoid
deleterious effects on reproductive parameters. Addition-
ally, lactation was not hormonally induced in the F1
progeny of this line because a study investigating the
puberty and reproductive characteristics of these animals
is currently underway.
In summary, we produced two transgenic goats with a
stably integrated hG-CSF gene that were capable of secret-
ing recombinant hG-CSF from the lactating mammary
gland without causing any harm to the animals’ health.
Additionally, both the male and female transgenic goats
are true founders as they were proven to be fertile and
capable of transmitting the hG-CSF gene to ﬁrst generation
progeny of each line. Additional investigations regarding
the phenotypic and genotypic characteristics of the 10 M
and 12 F lines are warranted. We  believe that the exper-
iments presented here provide an efﬁcient strategy that
may  be useful for the industrial production of recombinant
hG-CSF protein using transgenic goats.
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